F146 - Chronic Urticaria and Angioedema: What's New in Pathogenesis and Treatment
Monday, February 19; 3:30 PM - 5:30 PM
Following this course, the attendee should be able to:
- Discuss the pathophysiology of CIU
- Utilize Antihistamines for CIU
- Design a treatment plan for CIU patients resistant to antihistamines
This session will provide the attendee with up to date information regarding the pathophysiology of chronic idiopathic urticaria (CIU) and idiopathic angioedema as well as describe the appropriate use of antihistamines for these disorders. In addition, the attendee will learn about other treatment approaches for CIU and angioedema patients resistant to antihistamines.
- Baker, Diane Romayne, MD: Aimmune Therapeutics, Inc. – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); sanofi-aventis – O(Grants/Research Funding);
- Garritson, Emily Margaret, MD: no financial relationships exist with commercial interests.
- Leslie, Tabi Anika, MBBS: no financial relationships exist with commercial interests.
- Tharp, Michael D., MD: BestDoctors – C(Fees); Medical Information Network – F(S); Novartis Pharmaceuticals Corp. – C(H); Unilever Home & Personal Care USA – A(Grants/Research Funding);
Monday, February 19
Dr. Tharp / Introduction
Dr. Leslie / Pathophysiology of Urticaria and Angioedema
Dr. Baker / Workup for CIU and angioedema
Dr. Leslie / Use of antihistamines for CIU/angiodedema
Dr. Baker / Omalizumab for CIU
Dr. Garritson / Use of dapsone for CIU
Dr. Tharp / Other treatments for CIU
All faculty / Questions